Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.53 |
| ▸ | RXRA | P19793 | 9/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586193 | 0.93 | NR1H2 (0.56) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3569081 | 0.91 | NR1H2 (0.51) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL14621385 | 0.90 | NR1H2 (0.51) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL2257553 | 0.88 | NR1H2 (0.51) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3584362 | 0.87 | NR1H2 (0.51) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3583748 | 0.87 | NR1H2 (0.57) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3583853 | 0.87 | NR1H2 (0.50) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL2256135 | 0.86 | NR1H2 (0.54) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3584249 | 0.86 | RXRA (0.47) | NR1H2NR1H3RXRANTSR1GABRA2 | |
| SCHEMBL3588963 | 0.85 | NR1H2 (0.51) | NR1H2NR1H3RXRANTSR1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998995-B2 | LXR and FXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069367-A1 | LXR and FXR Modulators | EXELIXIS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| WO-2008073825-A1 | LXR AND FXR MODULATORS | EXELIXIS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069367-A1 | LXR and FXR Modulators | NR1H3, NR1H2, NR1H4 | NR1H2 2/4885NR1H3 1/4885RXRA 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.